Építés alatt – nem éles oldal
Belépés
Leállítva2. fázis

Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Pretreated Participants With Gastric Cancer

A legfontosabb adatok

Ki végzi
Sanofi
Hol
Belgium, Dél-Korea, Japán, Oroszország, Spanyolország és Törökország21 helyszín, 6 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Leállítva
Fázis
2. fázis
Résztvevők
35 fő vett részt
Kezdés
2021. nov. 16.
Befejezés
2024. nov. 5.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Ramucirumab (CYRAMZA®)
  • Tusamitamab ravtansine (SAR408701)
A regiszteradat frissítve
2025. augusztus 22.
Miért állt le
Sponsor decision, the decision is not related to any safety concern.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 28 feltétel megnézéseKevesebb

Ki vehet részt

  • Histologically or cytologically confirmed diagnosis of gastric or GEJ adenocarcinoma
  • Metastatic disease or locally advanced, unresectable disease
  • Participants who have measurable target lesion
  • Participants with high carcinoembryonic antigen-related cell adhesion molecule (CEACAM5) expression as per central assessment on tumor biospsy
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  • Female participant who agrees to use effective contraceptive methods during and for at least 7 months after the last dose of treatment administration
  • Male participant who agrees to use effective contraception methods during and for at least 4 months after the last dose of treatment administration
  • Signed informed consent

Ki nem vehet részt

  • Significant concomitant illness
  • Nonresolution of any prior treatment-related toxicity
  • Unresolved corneal disorder or any previous corneal disorder considered by an ophthalmologist to predict higher risk of drug-induced keratopathy
  • Major surgery within 28 days prior to Day 1/first IMP infusion; subcutaneous venous access device placement within 7 days prior to Day 1; or postoperative bleeding complications or wound complications from a surgical procedure performed in the last 2 months
  • History of gross hemoptysis (defined as bright red blood or ≥1/2 teaspoon) within 2 months before the first treatment administration
  • Any arterial thrombotic event, including myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack, within 6 months before the first administration of treatment administration
  • Serious or nonhealing wound, skin ulcer, or bone fracture within 28 days before the first administration of treatment administration
  • Gastrointestinal (GI) perforation and/or fistulae within 6 months prior to first administration of treatment administration
  • Significant bleeding disorders, vasculitis, or Grade 3-4 gastrointestinal (GI) bleeding within 3 months before the first administration of study intervention
  • Medical condition requiring concomitant administration of a medication with a narrow therapeutic window and metabolized by CYP450 or a strong CYP3A inhibitor
  • Concurrent treatment with any other anticancer therapy
  • Prior treatment targeting CEACAM5 or containing maytansinoid DM1 or DM4 or ramucirumab or taxane or targeting VEGF/VEGFR Poor organ function; The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial
  • Untreated brain metastases, leptomeningeal disease, or uncontrolled spinal cord compression
  • History within the last 3 years of an invasive malignancy other than that treated in this study
  • Known uncontrolled infection
  • History of uncontrolled hereditary or acquired thrombotic disorder or history of aneurism
  • Uncontrolled arterial hypertension (systolic ≥150 mmHg or diastolic ≥90 mmHg) despite standard medical management
  • Bowel obstruction, history or presence of inflammatory enteropathy or extensive intestinal resection Crohn's disease, ulcerative colitis, or chronic diarrhea
  • Use of contact lenses
  • Radiographic evidence of major airway or blood vessel invasion or intratumor cavitation

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

6 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Primary Objectives:

A teljes eredeti leírásKevesebb

Part 1: to confirm the recommended tusamitamab ravtansine loading dose Q2W in combination with ramucirumab in advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma population

Part 2: to assess the antitumor activity of tusamitamab ravtansine loading dose Q2W in combination with ramucirumab in advanced gastric or GEJ adenocarcinoma

Secondary Objectives:

* To assess safety and tolerability * To assess durability of response (DOR) * To assess progression-free survival (PFS) * To assess the disease control rate (DCR) * To assess the pharmacokinetics (PK) * To assess the immunogenicity

A vizsgálat csoportja

  • Tusamitamab ravtansine+RamucirumabA vizsgált kezelés

    Participants received ramucirumab 8 milligram/kilogram (mg/kg) via intravenous (IV) infusion followed by tusamitamab ravtansine loading dose at 170 mg/meter square (m\^2) via IV infusion on Cycle 1 Day 1 (each cycle was 2 weeks); and then ramucirumab 8 mg/kg via IV infusion followed by tusamitamab ravtansine 100 mg/m\^2 via IV infusion at Cycle 2 and every 2 weeks (Q2W) in all subsequent cycles until disease progression, unacceptable adverse event (AE), death, initiation of a new anticancer therapy, or the participant's or investigator's decision to stop the treatment.

    Kezelés: Ramucirumab (CYRAMZA®) és Tusamitamab ravtansine (SAR408701)

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Open-label Study of Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Participants Previously Treated for Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma With CEACAM5-positive Tumors
A regiszteradat frissítve
2025. augusztus 22.